A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors
Nabil Adra, David J. Vaughn, Lawrence H. Einhorn, Nasser H. Hanna, Samuel A. Funt, Matt Rosales, Ahsan M. Arozullah, Darren R. Feldman
Topics & Concepts
MedicineGerm cell tumorsChemotherapyInternal medicineRefractory (planetary science)ImmunohistochemistryGastroenterologyAdverse effectHistologyPathologyBiologyAstrobiologyTesticular diseases and treatmentsUrologic and reproductive health conditionsGlioma Diagnosis and Treatment